Immunotherapy with peptides

European Annals of Allergy and Clinical Immunology

Volumn 38, Issue 7, 2006, Pages 240-243

  Larche M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; EPITOPE; HLA DR2 ANTIGEN; IMMUNOGLOBULIN E; IPC 1; IPC 2; PEPTIDE DERIVATIVE; POLYPEPTIDE; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ALLERGIC ENCEPHALOMYELITIS; ANTIBODY RESPONSE; ARTICLE; CELL ACTIVATION; CHEMICAL MODIFICATION; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG TOLERANCE; ENGINEERING; GENETIC POLYMORPHISM; HLA SYSTEM; HUMAN; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MAST CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROPHYLAXIS; PROTEIN BINDING; PROTEIN SYNTHESIS; SENSITIZATION; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; PEPTIDES;

EID: 33750213229     PISSN: 03979148     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hoyne G.-F., O'Hehir R.-E., Wraith D.-C., Thomas W.-R., Lamb J.-R. (1993). - Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J. Exp. Med, 178:1783-1788.
2. Paas-Rozner M., Dayan M., Paas Y., Changeux J.-P., Wirguin I., Sela M., Mozes E. (2000). - Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice. Proc. Natl. Acad. Sci. U.S.A. 97:2168-2173.
3. Briner T.-J., Kuo M.-C., Keating K.-M., Rogers B.-L., Greenstein J.-L. (1993). - Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc. Natl. Acad. Sci. U.S.A. 90:7608-7612.
4. Astori M., von Garnier C., Kettner A., Dufour N., Corradin G., Spertini F. (2000). - Inducing tolerance by intranasal administration of long peptides in naive and primed CBA/J mice. J. Immunol. 165:3497-3505.
5. Staines N.-A., Harper N., Ward F.-J., Malmstrom V., Holmdahl R., Bansal S. (1996). - Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin. Exp. Immunol. 103:368-375.
6. Gaur A., Wiers B., Liu A., Rothbard J., Fathman C.-G. (1992). - Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 258:1491-1494.
7. Clayton J.-P., Gammon G.-M., Ando D.-G., Kono D.-H., Hood L., Sercarz E.-E. (1989). - Peptide-specific prevention of experimental allergic encephalomyelitis. Neonatal tolerance induced to the dominant T cell determinant of myelin basic protein. J. Exp. Med. 169:1681-1691.
8. Prakken B., Wauben M., van Kooten P., Anderton S., van Der Z.-R., Kuis W., van Eden W. (1998). - Nasal administration of arthritis-related T cell epitopes of heat shock protein 60 as a promising way for immunotherapy in chronic arthritis. Biotherapy 10:205-211.
9. Massey E.-J., Sundstedt A., Day M.-J., Corfield G., Anderton S., Wraith D.-C. (2002). - Intranasal peptide-induced peripheral tolerance: the role of IL-10 in regulatory T cell function within the context of experimental autoimmune encephalomyelitis. Vet. Immunol. Immunopathol. 87:357-372.
10. Burkhart C., Liu G., Metzler B., Wraith D.-C. (1998). - Modulation of cytokine production following intranasal administration of antigenic peptide. Transplant. Proc. 30:4186-4187.
11. Wiedermann U., Herz U., Vrtala S., Neuhaus-Steinmetz U., Renz H., Ebner C., Valenta R., Kraft D. (2001). - Mucosal tolerance induction with hypoallergenic molecules in a murine model of allergic asthma. Int. Arch. Allergy Immunol 124:391-394.
12. Warren K.-G., Catz I., Wucherpfennig K.-W. (1997). - Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J. Neurol. Sci. 152:31-38.
13. Kappos L., Comi G., Panitch H., Oger J., Antel J., Conlon P., Steinman L. (2000). - Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in relapsing MS Study Group. Nat. Med. 6:1176-1182.
14. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., Gran B., Eaton J., Antel J., Frank J.-A., McFarland H.-F., Martin R. (2000). - Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6:1167-1175.
15. Larche M., Wraith D.-C. (2005). - Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 11:S69-S76.
16. Norman P.-S., Ohman J.-L., Jr., Long A.-A., Creticos R.-S., Gefter M.-A., Shaked Z., Wood R.-A., Eggleston P.-A., Hafner K.-B., Rao P., Lichtenstein L.-M., Jones N.-H., Nicodemus C.-F. (1996). - Treatment of cat allergy with T-cell reactive peptides. Am. J. Respir. Crit Care Med. 154:1623-1628.
17. Marcotte G.-V., Braun C.-M., Norman P.-S., Nicodemus C.-R, Kagey-Sobotka A., Lichtenstein L.-M., Essayan D.-M. (1998). - Effects of peptide therapy on ex vivo T-cell responses. J. Allergy Clin. Immunol. 101:506-513.
18. Pene J., Desroches A., Paradis L., Lebel B., Farce M., Nicodemus C.-F., Yssel H., Bousquet J. (1998). - Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J. Allergy Clin. Immunol. 102:571-578.
19. Simons F.-E., Imada M., Li Y., Watson W.-T., HayGlass K.-T. (1996). - FeI d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int. Immunol. 8:1937-1945.
20. Maguire P., Nicodemus C., Robinson D., Aaronson D., Umetsu D.T. (1999). - The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin. Immunol. 93:222-231.
21. Muller U., Akdis C.-A., Fricker M., Akdis M., Blesken T., Bettens F., Blaser K. (1998). - Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 101:747-754.
22. Fellrath J.-M., Kettner A., Dufour N., Frigerio C., Schneeberger D., Leimgruber A., Corradin G., Spertini F. (2003). - Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J. Allergy Clin. Immunol. 111:854-861.
23. Haselden B.-M., Kay A.-B., Larche M. (1999). - Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J. Exp. Med. 189:1885-1894.
24. Southwood S., Sidney J., Kondo A., del Guercio M.-F., Appella E., Hoffman S., Kubo R.-T., Chesnut R.-W., Grey H.-M., Sette A. (1998.-) Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160:3363-3373.
25. Oldfield W.-L, Kay A.-B., Larche M. (2001). - Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 167:1734-1739.
26. Oldfield W.-L., Larche M., Kay A.-B. (2002). - Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 360:47-53.
27. Alexander C., Ying S., Kay B., Larche M. (2005). - Fel d 1-derived T cell peptide therapy induces recruitment of CD4CD25; CD4 interferon-gamma T helper type 1 cells to sites of allergen-induced late-phase skin reactions in catallergic subjects. Clin Exp. Allergy 35:52-58.
28. Alexander C., Tarzi, M., Larche M., Kay A.-B. - The effect of Fel d 1-derived T cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy, In press. 2005.
29. Verhoef A., Alexander C., Kay A.-B., Larche M. (2005). - T Cell Epitope Immunotherapy Induces a CD4+ T Cell Population with Regulatory Activity. PLoS. Medicine. 2, e78.